| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Schrodinger, Inc. Common Stock$15.8
+0.23 (+1.48%)
Market Cap
839.39 M
EPS
-1.41
P/E Ratio
-8.06 $
Value Trade
23.70 M
SEC Financials
Q1 2026Dilution Risk
Revenue
58.59 M
R&D Expenses
43.82 M
Operating CF
-14.83 M
Total Assets
634.19 M
Total Liabilities
320.64 M
Equity
313.55 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
398.96 M
Monthly Burn
4.95 M
Runway
79.3 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
937.87 K
52 Week Range
10.95 - 27.63
% held by Insiders
15.23 %
% held by Institutions
84.78 %
Enterprise Value
546.29 M
Total Shares
64.53 M
Short %
16.46 %
Float Shares
53.11 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SDGR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Schrodinger, Inc. Common Stock (SDGR) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
SDGR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SDGR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SDGR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SDGR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SDGR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SDGR
May 4, 2026Schrödinger to Participate in Upcoming May 2026 Investor Conferences
Schrödinger, Inc. (Nasdaq: SDGR) has announced its participation in several investor conferences scheduled for May 2026. The discussions will be accessible via the company's website and archived for 90 days post-event. Schrödinger is known for its advanced computational platform that aids in drug development and materials design.
Read more →-SDGR
May 4, 2026Schrödinger to Participate in Upcoming Investor Conferences
Schrödinger is set to participate in several upcoming investor conferences. The company aims to engage with investors and discuss its latest developments. Specific details about the conferences or topics of discussion were not provided in the article.
Read more →-SDGR
Apr 21, 2026Schrödinger to Announce First Quarter 2026 Financial Results on May 5
Schrödinger, Inc. (Nasdaq: SDGR) will report its first quarter 2026 financial results on May 5, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company's website. This event highlights the company's commitment to investor engagement and transparency.
Read more →-SDGR
Apr 17, 2026Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The details surrounding these grants were not elaborated upon in the article. This announcement is a procedural update related to compliance with Nasdaq regulations.
Read more →-SDGR
Feb 26, 2026Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results
Schrödinger, Inc. reported a total revenue of $256 million for 2025, with a notable 23% growth. The company is transitioning to a hosted software model to enhance revenue predictability, despite expecting short-term declines in software revenue. Looking ahead, Schrödinger aims to achieve positive adjusted EBITDA by the end of 2028, supported by its innovative platform and strong customer engagement.
Read more →-SDGR
Feb 18, 2026Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 18, 2026
Schrödinger, Inc. has announced the granting of stock options and restricted stock units to newly hired employees as part of its 2021 Inducement Equity Incentive Plan. The grants, totaling 9,600 stock options and 18,250 RSUs, were made to incentivize acceptance of employment. The stock options have a ten-year term and vest over four years, while the RSUs also vest over a similar period.
Read more →-SDGR
Feb 12, 2026Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
Schrödinger, Inc. will announce its fourth quarter and full-year 2025 financial results on February 25, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET. The event will be accessible via the company's website and archived for 90 days. Schrödinger focuses on molecular discovery through its advanced computational platform.
Read more →-SDGR
Jan 13, 2026Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
Schrödinger, Inc. has provided an update on its business progress for 2025 and outlined strategic priorities for 2026. The company aims to enhance its physics+AI computational platform and expand its drug discovery collaborations. Notably, new agreements with Lilly and Manas AI are expected to bolster its capabilities in addressing data scarcity in molecular discovery.
Read more →-SDGR
Jan 9, 2026Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign
Schrödinger, Inc. has announced a partnership with Eli Lilly to integrate the TuneLab platform into its LiveDesign informatics system. This collaboration is intended to enhance drug discovery by providing advanced AI capabilities to biotech companies. Schrödinger's platform aims to democratize access to computational tools, facilitating more efficient workflows in drug development.
Read more →Competitive Position
How SDGR ranks across every disease it competes inCompetitive Position is a premium feature
See how SDGR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial